Market Overview

Top Trending Tickers On StockTwits For January 27

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

Here's a look at the top tickers trending on StockTwits.com

Ariad Pharmaceuticals: Buyout rumors persist

On Friday, analysts at BMO Capital upgraded Ariad Pharmaceuticals (NASDAQ: ARIA) from Market Perform to Outperform with a price target raised to $14 from a previous $8. The analysts noted that the company's assets make the company an attractive buy out candidate from a large pharmaceutical company.

With no news announcements over the weekend, traders continue to speculate that the company will be bought out soon.

Shares were trading higher by one percent in the pre-market session.

Caterpillar: EPS and revenue beat

This morning, Caterpillar (NYSE: CAT) released its fourth quarter results. The company reported an EPS of $1.54, beating the consensus estimate of $1.28. Revenue of $14.4 billion beat the consensus estimate of $13.61 billion.

The company announced that it plans to buy back $1.7 billion worth of shares in the first quarter, fully completing its $7.5 billion authorization program. The company announced a new share buy back program of $10 billion that will expire at the end of 2018.

The company expects its 2014 revenue to be “about $56 billion in a range of plus or minus five percent.” The consensus is for revenue of $55.27 billion.

Shares were trading higher by seven percent in the pre-market session.

Herbalife: Approaching key price level

As the Herbaife (NYSE: HLF) pyramid scheme accusations continue to dominate the news headlines, traders on Stocktwits are paying close attention to the key $60 price level.

One user commented that $60 per share is a “critical juncture” as shares reached this level due to a “constant barrage of negative news and market sell offs.” However, a breach below $60 per share is “something longs should not only remain open to but also shift bias to.”

Shares were trading higher by 0.72 percent in the pre-market session, barely hovering over the key $60 price level.

Kansas City Southern: Analysts divided on earnings

On Friday, Kansas City Southern (NYSE: KSU) released its fourth quarter results. The company missed the consensus EPS by $0.07 and revenue came in $1.76 billion short of estimates.

This morning, analysts are divided in their analysis of the company.

Analysts at Buckingham upgraded shares to Neutral from Underperform with a $101 price target based on a valuation of call following Friday's 15 percent decline. Analysts at RBC Capital commented that the company's earnings are still poised to grow.

Analysts at Raymond James downgraded shares to Outperform from Strong Buy with a price target lowered to $109 from a previous $135. The analysts cited the company's fourth quarter as a reason for the downgrade.

Shares were trading higher by half a percent in the pre-market session.

Vodafone: No longer on the selling block

This morning, AT&T (NYSE: T) said that it has no intention of making an offer to acquire the British telecom operator.

In response to British rules and regulations, AT&T issued a statement to the London Stock Exchange confirming the company's intentions.

There has been previous speculation that AT&T was interested in pursuing M&A activity within the European market.

With AT&T's comments to the London Stock Exchange, the company is barred from making a substantial offer for the next six months.

Shares of Vodafone were trading lower by two percent in the pre-market session.

Posted-In: Ariad Pharmaceutical Rumours AT&T Vodafone Caterpillar Earnings Herbalife Herbalife China Herbalife Pyarmid Scheme Kansas City Southern EarningsNews Best of Benzinga

 

Related Articles (ARIA + CAT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters